Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease-Reference-Cited by-同舟云学术

Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease

Published:2014-08 Issue:8 Volume:26 Page:836-845
ISSN:0954-691X
Container-title:European Journal of Gastroenterology & Hepatology
language:en
Short-container-title:

Author:

Maasoumy Benjamin,Port Kerstin,Deterding Katja,Höner zu Siederdissen Christoph,Markova Antoaneta A.,Rogalska-Taranta Magdalena,Manns Michael P.,Wedemeyer Heiner,Cornberg Markus

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference9 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.;Mohd Hanafiah;Hepatology,2013

2. EASL clinical practice guidelines: management of hepatitis C virus infection.;J Hepatol,2011

3. Natural history of acute and chronic hepatitis C.;Maasoumy;Best Pract Res Clin Gastroenterol,2012

4. Treating viral hepatitis C: efficacy, side effects, and complications.;Manns;Gut,2006

5. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.;Chen;Clin Gastroenterol Hepatol,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breakthroughs in hepatitis C research: from discovery to cure;Nature Reviews Gastroenterology & Hepatology;2022-05-20

2. Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy;Open Forum Infectious Diseases;2020-02-01

3. Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment;Liver International;2017-10-14

4. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1–4 in an ambulatory care setting;American Journal of Health-System Pharmacy;2017-03-01

5. Diagnostics in hepatitis C: The end of response-guided therapy?;Journal of Hepatology;2016-10